Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices

Last updated: July 27, 2015
Sponsor: University of Padova
Overall Status: Trial Status Unknown

Phase

3

Condition

Vascular Diseases

Liver Disorders

Hepatic Fibrosis

Treatment

N/A

Clinical Study ID

NCT02508623
3250/AO/14
2014-000102-35
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to assess whether the add of Rifaximin in patients with liver cirrhosis and esophageal varices treated with a standard therapy with beta blockers, leads to a significant reduction of portal hypertension.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of liver cirrhosis (based on clinical, biochemical and radiological criteriawith or without liver biopsy)

  • Presence of esophageal varices at high risk of bleeding

  • Hepatic Venous Pressure Gradient > 12 mmHg.

  • 19≤ age ≤75

  • Informed Consent

Exclusion

Exclusion Criteria:

  • Patients already treated with beta blockers

  • Treatment with systemic antibiotics and/or non-absorbable intestinal antibiotics inthe previous two weeks

  • Bacterial infection, spontaneous bacterial peritonitis

  • overt hepatic encephalopathy in the last week

  • active gastrointestinal bleeding, or in the last week

  • active alcoholism or drug abuse in last 3 weeks

  • Acute Alcoholic Hepatitis

  • Hepatocellular carcinoma or other neoplasm

  • significant coronary artery disease (angina NYHA III/IV), congestive heart failure (NYHA III/IV), relevant cardiomyopathy, history of myocardial infarct within the last 12 months

  • Contraindications to the administration of beta blockers; allergy to Rifaximin

  • Pregnancy or breastfeeding

  • Refusal to participate

Study Design

Total Participants: 60
Study Start date:
July 01, 2015
Estimated Completion Date:
July 31, 2017

Study Description

It is well recognized that the gut flora may play an important role in the development of complications of liver cirrhosis, such as hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP) and variceal bleeding, which are are directly caused or aggravated by the translocation of enteric bacteria or their products into the blood of cirrhotic patients.Preliminary studies have shown that selective intestinal decontamination appears to ameliorate the hyperdynamic circulatory state of cirrhosis. The investigators hypothesize that a modulation of gut microbiota by administering a non-adsorbable antibiotic, in addition to beta-blockers, can be a safe strategy to reduce the portal pressure, influencing favorably hemodynamics of portal circulation. Thus, the purpose of this study is to evaluate if in patients with liver cirrhosis and esophageal varices at high risk of bleeding, Rifaximin, administered in addition to standard therapy with beta - blockers (propranolol), for a time of 60 days: leads to a significant reduction of Hepatic Venous Pressure Gradient (it will be assessed by hepatic vein catheterization), 2) modify the intestinal flora in favor of specific families of bacteria (it will be assessed by fecal microbiota analysis), 3) change systemic inflammatory responses (it will be assessed by serum pro-inflammatory cytokines) 4) change in cognitive functions (it will be assessed by neuropsychological and electroencephalogram evaluations).

Connect with a study center

  • Azienda Ospedaliera di Padova

    Padua, 35140
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.